Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.

Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis

Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has received a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for a new…

Clinical AI systems often include automated analysis of medical time series, such as electrocardiogram (ECG), to serve as valuable diagnostic decision support tools. While many cardiovascular diseases are traditionally measured…